Saiki I, Maeda H, Sakurai T, Murata J, Iida J, Kiso M, Hasegawa A, Azuma I
Institute of Immunological Science, Hokkaido University, Sapporo, Japan.
Cancer Immunol Immunother. 1989;29(2):101-8. doi: 10.1007/BF00199284.
We have investigated the endogenous production of a serum cytotoxic factor when recombinant interferon-gamma (rIFN-gamma) is combined with synthetic lipid A subunit analogs of low toxicity (GLA compounds). The cytotoxic activity of the serum was measured by the crystal violet staining method with L929 cells as a target. Intravenous administration of rIFN-gamma followed by intravenous administration of lipopolysaccharide induced the endogenous production of a cytotoxic factor in the serum. The priming effect of rIFN-gamma appeared immediately and persisted for approximately 20 h after the injection. Administration of lipopolysaccharide as a trigger enhanced the production of the cytotoxic factor in the serum maximally 2 h after the injection. The cytotoxic activity in the serum was completely inhibited by anti-(mouse tumor necrosis factor) (TNF) antibody. A synthetic lipid A subunit analog (GLA-60), which is much less toxic in its endotoxin activities than lipopolysaccharide or synthetic lipid A (compound 506), induced the endogenous production of serum TNF in rIFN-gamma-primed mice. GLA-60 entrapped within liposomes induced the production of serum TNF in rIFN-gamma-primed mice more effectively than GLA-60 solubilized in phosphate-buffered saline. Intravenous or intranasal administrations of rIFN-gamma followed by intranasal administration of GLA-60 produced TNF in the lung washing fluid but not in the serum, indicating that TNF production can be induced locally rather than systemically by the alteration of the administration route of the primer and trigger. These results indicate that GLA-60, a lipid A subunit analog of low toxicity, is a beneficial triggering agent in the production of endogenous TNF, as well as having other immunopharmacological properties, and may provide a basis for cancer (metastases) treatment as a result of its ability to induce endogenous TNF.
我们研究了重组干扰素-γ(rIFN-γ)与低毒性合成脂多糖A亚基类似物(GLA化合物)联合使用时血清细胞毒性因子的内源性产生情况。以L929细胞为靶细胞,采用结晶紫染色法测定血清的细胞毒性活性。静脉注射rIFN-γ后再静脉注射脂多糖可诱导血清中细胞毒性因子的内源性产生。rIFN-γ的启动效应在注射后立即出现,并持续约20小时。注射脂多糖作为触发剂可在注射后最大2小时增强血清中细胞毒性因子的产生。血清中的细胞毒性活性被抗(小鼠肿瘤坏死因子)(TNF)抗体完全抑制。一种合成脂多糖A亚基类似物(GLA-60),其在内毒素活性方面比脂多糖或合成脂多糖(化合物506)毒性小得多,可在rIFN-γ预处理的小鼠中诱导血清TNF的内源性产生。包裹在脂质体中的GLA-60比溶解在磷酸盐缓冲盐水中的GLA-60更有效地在rIFN-γ预处理的小鼠中诱导血清TNF的产生。静脉或鼻内注射rIFN-γ后再鼻内注射GLA-60可在肺灌洗液中产生TNF,但血清中未产生,这表明通过改变引发剂和触发剂的给药途径,TNF的产生可以局部而非全身诱导。这些结果表明,低毒性的脂多糖A亚基类似物GLA-60是内源性TNF产生中的一种有益触发剂,以及具有其他免疫药理学特性,并且由于其诱导内源性TNF的能力,可能为癌症(转移)治疗提供基础。